Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Phase 2 Terminated
11 enrolled 13 charts
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Phase 1 Terminated
8 enrolled
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Phase 1/2 Terminated
10 enrolled 15 charts
Dasatinib In Waldenström Macroglobulinemia
Phase 1 Terminated
3 enrolled 13 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase 1/2 Terminated
7 enrolled 9 charts
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phase 1/2 Terminated
1 enrolled 5 charts
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Phase 2 Terminated
5 enrolled 12 charts
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
Phase 2 Terminated
31 enrolled
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase 1/2 Terminated
20 enrolled 9 charts
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase 2 Terminated
12 enrolled 12 charts
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Personalized Treatment Selection for Metastatic Breast Cancer
Phase 2 Terminated
97 enrolled 7 charts
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Terminated
12 enrolled
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase 1 Terminated
1 enrolled 7 charts
BMS-CA180105
Phase 1/2 Terminated
3 enrolled 3 charts
Dasatinib
Phase 1 Terminated
22 enrolled 8 charts
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
Phase 1 Terminated
16 enrolled
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Phase 2 Terminated
7 enrolled 5 charts
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Phase 2 Terminated
1 enrolled 3 charts
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
Phase 2 Terminated
21 enrolled 8 charts
Dasatinib in Polycythemia Vera
Phase 2 Terminated
10 enrolled 7 charts
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Phase 2 Terminated
10 enrolled 6 charts
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Phase 1 Terminated
2 enrolled
Gem/Dsat
Phase 1 Terminated
30 enrolled
TOP0706
Phase 2 Terminated
2 enrolled 4 charts
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Phase 1/2 Terminated
11 enrolled 6 charts
ARS
Phase 2 Terminated
57 enrolled 8 charts
Dasatinib in Advanced Squamous Cell Lung Cancer
Phase 2 Terminated
5 enrolled 7 charts
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Phase 2 Terminated
7 enrolled 7 charts
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
Phase 2 Terminated
22 enrolled 7 charts
D-MP
Phase 2 Terminated
8 enrolled